Page last updated: 2024-09-03

lestaurtinib and Erythremia

lestaurtinib has been researched along with Erythremia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fancher, KM; Green, MR; Newton, MD	1
Bensen-Kennedy, D; Carroll, M; Clementi, R; Hexner, E; Hoffman, R; Luger, S; Mascarenhas, J; Moliterno, A; Roboz, G	1
Cortes, J; Estrov, Z; Garcia-Manero, G; Jain, N; Kantarjian, HM; Kennedy, D; Manshouri, T; Santos, FP; Thomas, DA; Verstovsek, S	1

Reviews

1 review(s) available for lestaurtinib and Erythremia

Article	Year
Off-Target Effects of BCR-ABL and JAK2 Inhibitors. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant	2016

Article

Year

Off-Target Effects of BCR-ABL and JAK2 Inhibitors.

American journal of clinical oncology, 2016, Volume: 39, Issue:1

Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant

2016

Trials

2 trial(s) available for lestaurtinib and Erythremia

Article	Year
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology, 2014, Volume: 164, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Female; Furans; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Thrombocythemia, Essential; Treatment Outcome	2014
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010, Feb-11, Volume: 115, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blotting, Western; Carbazoles; Cytokines; Female; Furans; Humans; Janus Kinase 2; Male; Middle Aged; Neoplasm Staging; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein-Tyrosine Kinases; Survival Rate; Thrombocythemia, Essential; Treatment Outcome	2010

Article

Year

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.

British journal of haematology, 2014, Volume: 164, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Carbazoles; Female; Furans; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Thrombocythemia, Essential; Treatment Outcome

2014

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Blood, 2010, Feb-11, Volume: 115, Issue:6

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blotting, Western; Carbazoles; Cytokines; Female; Furans; Humans; Janus Kinase 2; Male; Middle Aged; Neoplasm Staging; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein-Tyrosine Kinases; Survival Rate; Thrombocythemia, Essential; Treatment Outcome

2010